Cybercrime is evolving at an unprecedented rate, projected to cost the global economy $13.8 trillion by 2028.
With ransomware attacks, AI-driven hacking, and state-sponsored cyber warfare on the rise, governments and Fortune 500 companies are scrambling for solutions.
And one company—still under the radar—is emerging as a critical force in this digital arms race.
They’re already trusted by the U.S. and Canadian governments, Fortune 500 companies, and some of the biggest names in tech.
Despite their cutting-edge AI-driven security platform, rapidly growing contracts, and major industry partnerships, they’ve kept a low profile—for now.
The Future of Cybersecurity is Here
This high-growth cybersecurity company has developed a proprietary AI-powered platform that is redefining digital security.
🔹 It’s not another firewall. It’s not an antivirus program.
🔹 It’s an AI-driven security system that neutralizes cyber threats before they even start.
Their next-generation platform integrates behavioral biometrics, real-time authentication, and zero-trust security to eliminate human error and proactively stop attacks.
And their track record speaks for itself.
They’ve already secured contracts with:
✅ NASA
✅ The U.S. Department of Defense
✅ The Department of Homeland Security
✅ Tech giants like Microsoft, Salesforce, and Dell
This company is quickly becoming the cybersecurity partner of choice for governments, critical infrastructure, and major enterprises.
Government-Backed. Enterprise-Approved. AI-Powered.
$70M+ in revenue last year, with contracts growing at a rapid pace.
A $19.3M contract with an S&P 500 semiconductor company—the largest in the company’s history.
$22.9M in new sales year-to-date (October 2024).
Critical Services Division growing at 70%+ YoY, driving high-margin revenue expansion.
Strategic partnerships with cybersecurity giants like CrowdStrike and TD SYNNEX to expand its footprint.
A leadership team stacked with former NSA, intelligence, and Fortune 500 security experts.
An AI-powered security platform built for enterprises and government agencies struggling with cybersecurity talent shortages.
Why This Cybersecurity Stock is Still Under the Radar
Despite its growing contracts, increasing revenue, and industry-leading technology, this company remains significantly undervalued compared to cybersecurity peers.
🔹 Major cybersecurity firms trade at 5x-10x revenue multiples, while this company trades at less than 0.4x revenue.
🔹 They’ve already secured deals with industry giants, yet institutional money hasn’t fully caught on—yet.
The cybersecurity market is projected to hit $2 trillion annually, and with a global shortage of 4 million cybersecurity professionals, businesses are racing to secure AI-driven, automated security solutions.
This company already has a foothold in the most critical sectors, and its contracts prove it.
The Opportunity Won’t Stay Under Wraps for Long
📌 Want to know the name and ticker symbol of this rising cybersecurity leader?
📌 Why AI-driven cybersecurity is one of the biggest investment trends of the decade?
Simply enter your email below to unlock the full breakdown of this undervalued, high-growth cybersecurity stock—before Wall Street catches on.
DISCLAIMER
1. General Information and Liability
This landing page is provided and maintained by Fairfax Partners Inc. ("Fairfax") exclusively for informational purposes related to Plurilock Security Inc.("Plurilock"). The information contained herein is based on publicly available, non-material information sourced from company filings, news releases, and third-party reports.
Fairfax assumes no responsibility for the accuracy, completeness, or timeliness of any information presented on this page. No guarantee is made regarding the reliability of the data, and no assurance is given that projections or forward-looking statements will be realized.
Fairfax does not control Plurilock’s corporate decisions, operations, or strategic direction. This page and its contents do not constitute an official company communication from Plurilock Security Inc.
2. No Endorsement or Financial Advice
Fairfax does not own shares or any other financial interests in Plurilock Security Inc. Our role is strictly limited to the creation, maintenance, and promotion of this landing page as part of a sponsored campaign.
Fairfax does not provide financial, legal, or investment advice and does not recommend the purchase, sale, or holding of any securities. This page and associated materials should not be construed as investment advice, an offer to sell, or a solicitation to buy securities.
Compensation Disclosure
Fairfax Partners Inc. was compensated CA$120,000 by Plurilock Security Inc. for its services in managing and promoting this investor awareness campaign across various digital platforms, including but not limited to Facebook, YouTube, TikTok, Instagram, and Google Ads.
This compensation should be considered a material conflict of interest that may impact the objectivity of this content.
3. Investment Risks
Investing in early-stage companies, including Plurilock Security Inc., involves significant risks and may result in the loss of principal investment. Key risks include, but are not limited to:
The early-stage nature of Plurilock’s drug pipeline, which remains preclinical and is subject to development risks.
Market volatility and the potential for stock price fluctuations due to external factors.
Regulatory approvals, clinical trial results, and drug efficacy uncertainties.
The potential inability to secure future funding for clinical trials and commercialization.
The high-risk nature of AI-driven drug discovery, which is still an emerging field in biotechnology.
Neither Fairfax nor Plurilock’s Therapeutics Inc. assumes responsibility for any direct, indirect, or consequential financial losses incurred by investors relying on this information.
4. Forward-Looking Statements
This landing page and associated marketing materials may contain forward-looking statements within the meaning of applicable securities laws. Forward-looking statements reflect current expectations regarding future events, business growth, potential partnerships, regulatory approvals, clinical trial progress, and market expansion.
Risks Associated with Forward-Looking Statements
These statements involve known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially from projections. Factors that may impact future performance include, but are not limited to:
Changes in market conditions and regulatory environments.
The success or failure of AI-generated drug candidates during testing phases.
The availability of funding for continued research and development.
Delays in securing clinical trial approvals or pharmaceutical partnerships.
Rakovina Therapeutics Inc. does not undertake any obligation to update forward-looking statements unless required by law. Additional details can be found in Rakovina’s official SEDAR+ filings at www.sedarplus.ca.
5. Due Diligence and Professional Advice
Investors are strongly advised to perform independent due diligence before making investment decisions. This includes, but is not limited to:
Reviewing Rakovina’s SEDAR+ filings, investor presentations, and press releases.
Consulting licensed financial advisors or legal professionals regarding potential risks.
Understanding the early-stage nature of Rakovina’s drug development and associated challenges.
No information on this page should be used as a substitute for independent professional advice.
6. No Offer or Solicitation
This landing page and related marketing materials do not constitute an offer to sell or a solicitation to buy any securities, nor should they be interpreted as such. Any decision to invest in Rakovina Therapeutics Inc. should be made independently, based on a review of official company filings and independent financial consultation.
7. Share Ownership & Trading Activity Disclosure
Neither Fairfax Partners Inc. nor its affiliates own shares in Rakovina Therapeutics Inc.
Third parties, investors, and affiliates of Rakovina may buy or sell shares before, during, or after this marketing campaign.
Share prices may increase temporarily due to heightened investor awareness but may also experience declines post-campaign.
Frequent fluctuations in trading volume and price are common in microcap securities following investor awareness initiatives.
8. Fairfax’s Role and Responsibilities
Fairfax’s role in this campaign is strictly limited to information dissemination as directed by Rakovina Therapeutics Inc. Fairfax:
Does not control Rakovina’s operations or business decisions.
Is not responsible for the accuracy of third-party content or Rakovina’s public filings.
Is not liable for any financial losses resulting from investments based on this campaign.
Fairfax assumes no responsibility for errors, omissions, or misstatements in the provided materials.
9. Acknowledgment & Acceptance
By accessing this landing page and its content, you acknowledge and agree to:
Read and understand this legal disclaimer in its entirety.
Accept all risks associated with investing in Rakovina Therapeutics Inc.
Recognize Fairfax’s role as a paid marketing firm and the potential for bias.
Your continued use of this page constitutes acceptance of these terms. If you do not agree with this disclaimer, you should discontinue use immediately.
10. Intellectual Property & External Links
“Fairfax Partners Inc.” is the trademark of the Publisher.
All third-party trademarks belong to their respective owners.
Fairfax is not affiliated, connected, or associated with Rakovina Therapeutics Inc. beyond its marketing services.
External links are provided for reference but do not constitute endorsements of third-party content.
For official Rakovina Therapeutics Inc. filings, visit www.sedarplus.ca.